Jennifer King
Head of Business Development

    Jennifer King is Head of Business Development at Replay. She has over 20 years of operating experience in the biopharmaceutical industry. She provides business development and strategic support for biotechnology companies and other key stakeholders, with a focus on cutting edge technologies and orphan indications. From 2015 to 2019 Jenn served at Intellia Therapeutics, a CRISPR Cas9 genome editing company, completing her tenure as Senior Vice President for Business Development. Jenn founded and grew the Business Development and New Product Commercialization groups at Intellia. She was responsible for accessing external sources of innovation, establishing the company’s key industry and acaedmic partnerships, overseeing the alliance management activities for these partnerships and developing commercial strategies and frameworks for Intellia’s genome editing platform.

    Prior to her joining Intellia in 2015, Jenn held the position of Senior Director of Business Development at Shire Plc, (now Takeda) where she was responsible for the sourcing, initial evaluation and negotiation of licensing and acquisition opportunities within the company’s corporate development group. She previously worked in Shire’s rare disease commercial organization as a Global Brand Director for two clinical stage programs and served as its Director of New Products, where she was responsible for providing commercial guidance to development and research stage projects, as well as evaluating the commercial attractiveness of business development opportunities. Before joining Shire in 2006, Jennifer held a variety of commercial roles in at Millennium Pharmaceuticals; most notably as the Product Manager for the US launch of VELCADE®. Jennifer received her B.S. in Biology from the Massachusetts Institute of Technology, earned a Ph.D. in Developmental Biology at the Stanford University School of Medicine, and was awarded her MBA by Northeastern University.

    Join Replay

    Help us to author the future of genomic medicine